EGFR and non-small cell lung carcinoma: Additionally, MET protein activation has been associated with primary resistance to EGFR tyrosine kinase inhibitor (TKI) therapy in NSCLC patients (Fig 1).[13, 37] These observations have initiated a scientific debate about novel bispecific EGFR/MET inhibitors to obtain better therapeutic results.